Healthcare / Medical Instruments & SuppliesNasdaqGS
$412.26
-12.38 (-2.92%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $1.3B · quality 57.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$146.0B
P/E
50.0x
↑EV/EBITDA
40.3x
↑ROE
N/A
•Gross Margin
66.0%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2007–2025 · 18 años de histórico normalizado
Revenue CAGR
+17.0%
FCF CAGR
—
FCF margin
24.7%
FCF / Net income
—
Latest source
Provider fallback
Margin decomposition
Último año: revenue $10.06B · net income — · FCF $2.49B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||||
| Revenue | $10.06B | $10.06B | $8.35B | $7.12B | $6.22B | $5.71B | $4.36B | $4.48B | $3.72B | $3.14B | $2.71B | $2.38B | $2.13B | $2.27B | $2.18B | $1.76B | $1.41B | $1.05B | $874.9M | $600.8M |
| Net Income | — | — | — | — | — | $1.70B | $1.06B | $1.38B | $1.13B | $670.9M | $738.3M | $588.8M | $418.8M | $671.0M | $656.6M | $495.1M | $381.8M | $232.6M | $204.3M | $144.5M |
| EBITDA | $3.62B | $3.62B | $2.85B | $2.22B | $1.94B | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS | 7.87 | 7.87 | 6.42 | 5.03 | 3.65 | 4.66 | 2.94 | 3.85 | 3.16 | 1.92 | 2.09 | 1.73 | 1.23 | 1.86 | 1.78 | 1.37 | 1.05 | 0.66 | 0.57 | 0.41 |
| Gross Margin | 66.0% | 66.0% | 67.5% | 66.4% | 67.4% | 69.3% | 65.6% | 69.4% | 69.9% | 70.2% | 69.9% | 66.2% | 66.3% | 70.4% | 72.1% | 72.5% | 72.9% | 71.4% | 71.0% | 69.0% |
| Operating Margin | 29.3% | 29.3% | 28.1% | 24.8% | 25.3% | 31.9% | 24.1% | 30.7% | 32.2% | 33.9% | 35.1% | 31.0% | 25.6% | 37.6% | 40.3% | 39.5% | 39.3% | 35.9% | 35.5% | 34.4% |
| Net Margin | — | — | — | — | — | 29.9% | 24.3% | 30.8% | 30.3% | 21.4% | 27.3% | 24.7% | 19.6% | 29.6% | 30.1% | 28.2% | 27.0% | 22.1% | 23.4% | 24.1% |
| Balance Sheet | ||||||||||||||||||||
| Current Ratio | 4.61 | 4.61 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||||
| Free Cash Flow | $2.49B | $2.49B | $1.30B | $749.6M | $958.4M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Returns | ||||||||||||||||||||
| ROE | — | — | — | — | — | 14.3% | 10.9% | 16.7% | 16.9% | 14.0% | 12.8% | 13.6% | 12.4% | 19.2% | 18.3% | 18.7% | 18.7% | 15.1% | 16.1% | 16.3% |
| Valuation | ||||||||||||||||||||
| P/E | 49.97 | 49.97 | 83.38 | 64.12 | 74.08 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 40.35 | 40.35 | 67.31 | 50.64 | 49.57 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 8.39 | 8.39 | 11.79 | 8.66 | 8.86 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||||
| Revenue Growth | 20.5% | 20.5% | 17.2% | 14.5% | — | 31.0% | -2.7% | 20.3% | 18.7% | 16.0% | 13.5% | 11.9% | -5.9% | 4.0% | 24.0% | 24.4% | 34.3% | 20.3% | 45.6% | — |
| EPS Growth | 22.6% | 22.6% | 27.6% | 37.8% | — | 58.5% | -23.6% | 21.7% | 64.5% | -7.8% | 20.8% | 39.9% | -33.6% | 4.7% | 29.7% | 30.1% | 59.7% | 15.8% | 38.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
66.9%
EPS terminal req.
$36.58
Spread vs growth
-44.3%
5Y implied EPS CAGR
41.3%
EPS terminal req.
$44.26
Spread vs growth
-18.7%
10Y implied EPS CAGR
24.7%
EPS terminal req.
$71.29
Spread vs growth
-2.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-25.4%
Start / end P/E
86.0x → 52.4x
EPS bridge
6.42 → 7.87
Residual
-8.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.